306 related articles for article (PubMed ID: 32999149)
21. Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR).
Fawwaz M; Mishiro K; Nishii R; Sawazaki I; Shiba K; Kinuya S; Ogawa K
Molecules; 2020 Jun; 25(12):. PubMed ID: 32599930
[TBL] [Abstract][Full Text] [Related]
22. Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
Qin X; Li Z; Yang L; Liu P; Hu L; Zeng C; Pan Z
Bioorg Med Chem; 2016 Jul; 24(13):2871-2881. PubMed ID: 27234887
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H
Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y
Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886
[TBL] [Abstract][Full Text] [Related]
24. Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR
Shen J; Zhang T; Zhu SJ; Sun M; Tong L; Lai M; Zhang R; Xu W; Wu R; Ding J; Yun CH; Xie H; Lu X; Ding K
J Med Chem; 2019 Aug; 62(15):7302-7308. PubMed ID: 31298540
[TBL] [Abstract][Full Text] [Related]
25. Insights into the Overcoming EGFR
Zhang X; He J; Xu S; Fu L; Zheng P; Xu S; Pan Q; Zhu W
ChemMedChem; 2024 May; 19(9):e202300634. PubMed ID: 38351876
[TBL] [Abstract][Full Text] [Related]
26. Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights.
Suriya U; Mahalapbutr P; Wimonsong W; Yotphan S; Choowongkomon K; Rungrotmongkol T
Molecules; 2022 Dec; 27(24):. PubMed ID: 36558033
[TBL] [Abstract][Full Text] [Related]
27. Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment.
Wang C; Wang X; Huang Z; Wang T; Nie Y; Yang S; Xiang R; Fan Y
Eur J Med Chem; 2022 Jul; 237():114381. PubMed ID: 35447433
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation.
Zhang B; Xu Z; Liu Q; Xia S; Liu Z; Liao Z; Gou S
Bioorg Chem; 2021 Dec; 117():105420. PubMed ID: 34655841
[TBL] [Abstract][Full Text] [Related]
29. Novel bioactive 2-phenyl-4-aminopyrimidine derivatives as EGFR
Xu S; Zhou Z; He J; Guo J; Huang X; An Y; Pan Q; Xu S; Zhu W
Arch Pharm (Weinheim); 2024 Feb; 357(2):e2300460. PubMed ID: 38009481
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFR
Fang H; Wu Y; Xiao Q; He D; Zhou T; Liu W; Yang CH; Xie Y
Bioorg Med Chem Lett; 2022 Sep; 72():128729. PubMed ID: 35413415
[TBL] [Abstract][Full Text] [Related]
31. Identification of a novel nitroflavone-based scaffold for designing mutant-selective EGFR tyrosine kinase inhibitors targeting T790M and C797S resistance in advanced NSCLC.
Cristina M; Emiliano L; Leonardo S; Giulia S; Roberta G; Adolfo A; Marta SS; Paola S; Samuele R; Pierluigi S; Massimo M; Giovanna M
Bioorg Chem; 2022 Dec; 129():106219. PubMed ID: 36308853
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR
Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y
Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457
[TBL] [Abstract][Full Text] [Related]
33. Discovery of novel 4-arylamino-quinazoline derivatives as EGFR
Gan W; Wang C; Pan Q; Li Y; Guo Y; Fan D; Peng Y; Rao Z; Xu S; Zheng P; Zhu W
Bioorg Chem; 2022 Oct; 127():105994. PubMed ID: 35792314
[TBL] [Abstract][Full Text] [Related]
34. Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation.
Zhu Y; Ye X; Wu Y; Shen H; Cai Z; Xia F; Min W; Hou Y; Wang L; Wang X; Xiao Y; Yang P
J Med Chem; 2024 May; 67(9):7283-7300. PubMed ID: 38676656
[TBL] [Abstract][Full Text] [Related]
35. Psorachromene induces apoptosis and suppresses tumor growth in NSCLC cells harboring EGFR L858R/T790M/C797S.
Wang TH; Leu YL; Chen CC; Li HJ; Yang SC; Huang KY; Chen CY
Phytother Res; 2022 May; 36(5):2116-2126. PubMed ID: 35229911
[TBL] [Abstract][Full Text] [Related]
36. The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
Chen L; Chi F; Wang T; Wang N; Li W; Liu K; Shu X; Ma X; Xu Y
Bioorg Med Chem; 2018 Dec; 26(23-24):6087-6095. PubMed ID: 30471829
[TBL] [Abstract][Full Text] [Related]
37. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
Kashima K; Kawauchi H; Tanimura H; Tachibana Y; Chiba T; Torizawa T; Sakamoto H
Mol Cancer Ther; 2020 Nov; 19(11):2288-2297. PubMed ID: 32943545
[TBL] [Abstract][Full Text] [Related]
38. Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors.
Zhou F; Zhang L; Jin Y; Liu W; Cheng P; He X; Xie J; Shen S; Lei J; Ji H; Hu Y; Liu Y; Cui Y; Lv Q; Lan J
Bioorg Med Chem Lett; 2018 Apr; 28(7):1257-1261. PubMed ID: 29534926
[TBL] [Abstract][Full Text] [Related]
39. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
[TBL] [Abstract][Full Text] [Related]
40. Novel anilinopyrimidine derivatives as potential EGFR
Guo Y; Gao B; Gao P; Fang L; Gou S
Bioorg Med Chem; 2022 Sep; 70():116907. PubMed ID: 35810715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]